Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people who have an average survival time of around 14 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Strobel, Hannah, Baisch, Tim, Fitzel, Rahel, Schilberg, Katharina, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783999/
https://www.ncbi.nlm.nih.gov/pubmed/31505812
http://dx.doi.org/10.3390/biomedicines7030069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783999/
https://www.ncbi.nlm.nih.gov/pubmed/31505812
http://dx.doi.org/10.3390/biomedicines7030069

Ejemplares similares